Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 7/20 | 0.46 |
| ▸ | GLA known ✓ | P06280 | 3/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.37 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.37 |
| ▸ | ALK known ✓ | Q9UM73 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5006407 | 0.98 | MAOA (0.45) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL251439 | 0.98 | MAOA (0.47) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL17144907 | 0.98 | MAOA (0.47) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL31268130 | 0.98 | MAOA (0.47) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL2755535 | 0.90 | MAOA (0.41) | MAOAKDM4EALDH1A1GLAMAPT | |
| Hydrochloric Acid SCHEMBL31683811 | 0.88 | ALDH1A1 (0.36) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL18396959 | 0.87 | KDM4E (0.45) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL3240735 | 0.87 | ACHE (0.46) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL28933503 | 0.87 | PDE4D (0.44) | MAOAKDM4EALDH1A1GLAMAPT | |
| SCHEMBL30019618 | 0.87 | PDE4D (0.44) | MAOAKDM4EALDH1A1GLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060294-A1 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS | AUSPEX PHARMACEUTICALS LLC | 2023-03-02 | — | — | US | claimed |
| EP-3394057-B1 | SYNTHETIC METHOD FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]LSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | NEUROCRINE BIOSCIENCES INC (US) | 2022-03-30 | — | — | EP | claimed |
| CN-111960999-B | Synthetic method of tetrabenazine intermediate | 暨明医药科技（苏州）有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-110845410-B | Method for preparing 6, 7-dimethoxy-3, 4-dihydroisoquinoline hydrochloride by one-pot method | 暨明医药科技（苏州）有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-111960999-A | Synthetic method of tetrabenazine intermediate | 暨明医药科技（苏州）有限公司 | 2020-11-20 | — | — | CN | claimed |
| US-20200347008-A1 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. | 2020-11-05 | — | — | US | claimed |
| CN-110845410-A | Method for preparing 6, 7-dimethoxy-3, 4-dihydroisoquinoline hydrochloride by one-pot method | 暨明医药科技（苏州）有限公司 | 2020-02-28 | — | — | CN | claimed |
| EP-3394057-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | Neurocrine Biosciences Inc. (US) | 2018-10-31 | — | — | EP | claimed |
| CN-107698582-A | A kind of synthetic method of tetrabenazine and its intermediate | 北京恒瑞康达医药科技发展有限公司 | 2018-02-16 | — | — | CN | claimed |
| US-20170197957-A1 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS | AUSPEX PHARMACEUTICALS LLC | 2017-07-13 | — | — | US | claimed |
| WO-2017112857-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| CN-102260255-B | Simple and convenient synthesis method of 9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-3-isobutyl-2H-benzo[a] quinolizidine-2-ketone | JIANGSU INST OF NUCLEAR MED | 2013-07-10 | — | — | CN | claimed |
| CN-102260255-A | Simple and convenient synthesis method of 9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-3-isobutyl-2H-benzo[a] quinolizidine-2-ketone | — | 2011-11-30 | — | — | CN | claimed |
| US-12077487-B2 | Methods of manufacturing benzoquinoline compounds | AUSPEX PHARMACEUTICALS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240239791-A1 | PROCESSES FOR THE SYNTHESIS OF VALBENAZINE | NEUROCRINE BIOSCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-117736203-A | Method for synthesizing valphenazine | 纽罗克里生物科学有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-4678792-A | ANTITHROMBIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-07-07 | — | — | US | disclosed |
| US-4096147-A | ANTIDEPRESSANTS, ANTIPARKINSON AGENTS | RICHARDSON-MERRELL INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4052403-A | PSYCHOSEDATIVE | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1977-10-04 | — | — | US | disclosed |
| US-3983122-A | FROM CYCLOALKENYL KETONE AND DIHYDROISOQUINOLINE, ANTIDEPRESSANT | RICHARDSON-MERRELL INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347008-A1 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS | SLC18A2, SLC18A1, SLC6A2 | MAOA 25/4885GLA 4427/4885GAA 234/4885 |
| US-20240239791-A1 | PROCESSES FOR THE SYNTHESIS OF VALBENAZINE | SLC18A2, SLC18A3, SLC6A3 | MAOA 467/4885GLA 4432/4885GAA 512/4885 |
| US-12077487-B2 | Methods of manufacturing benzoquinoline compounds | SLC18A2, SLC18A1, SLC6A2 | MAOA 25/4885GLA 4427/4885GAA 234/4885 |
| US-20170197957-A1 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS | SLC18A2, SLC18A1, SLC6A2 | MAOA 25/4885GLA 4427/4885GAA 234/4885 |
| US-20230060294-A1 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS | SLC18A2, SLC18A1, SLC6A2 | MAOA 25/4885GLA 4427/4885GAA 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.